GCP
OMED

GSA Capital Partners’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

GSA Capital Partners’s Portfolio OMED Stock Details OMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-13,773
Closed -$56K – 2007
2017
Q4 		$56K Buy
+13,773
New +$59.9K ﹤0.01% 1498

Other funds holding OMED

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

GSA Capital Partners's OMED Position: Q1 2018 in Review

GSA Capital Partners sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q1 2018, closing a stake of 13,773 shares — an estimated $56K sold.

GSA Capital Partners first reported a position in OMED in Q4 2017 and held it in 1 quarter. The position peaked at $56K in Q4 2017. 66 funds tracked by Wall St. Rank hold OMED as of Q1 2018.

  • GSA Capital Partners reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
  • GSA Capital Partners sold 13,773 OncoMed Pharmaceuticals, Inc. shares in Q1 2018, an estimated $56K.
  • GSA Capital Partners first reported a position in OncoMed Pharmaceuticals, Inc. in Q4 2017 and held it in 1 quarter.
  • GSA Capital Partners's OncoMed Pharmaceuticals, Inc. position peaked at $56K in Q4 2017.
  • 66 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q1 2018.

Based on GSA Capital Partners's 13F filing for Q1 2018, filed 11 May 2018.